Tatva Chintan Pharma Chem share price today

Tatva Chintan Pharma Chem Ltd's share price was ₹1,690.20 at the close on 4 November 2026. It has been rising for 27 weeks. That is 14.6% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Tatva Chintan Pharma Chem Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹1,090 and ₹1,944, and at that close it sat 70% of the way up from that low.

Over the last 5.3 years the share price moved −25% while the NIFTY 500 moved +57%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 8 quarters in a row, highest quarterly profit in 16 quarters and highest quarterly revenue in 16 quarters.

1. Revenue up on a year earlier for 8 quarters in a row

   In the September 2026 quarter revenue was ₹217 crore, +75% on a year earlier.

2. Highest quarterly profit in 16 quarters

   Profit of ₹21 crore in the September 2026 quarter is the highest of the last 16 quarters.

3. Highest quarterly revenue in 16 quarters

   Revenue of ₹217 crore in the September 2026 quarter is the highest of the last 16 quarters.

For July to September 2026 (the quarter ended 30 September 2026), Tatva Chintan Pharma Chem reported revenue of ₹217 crore, up 75.0% from ₹124 crore a year earlier, and a profit of ₹21.0 crore, up 110.0% from ₹10.0 crore.

Tatva Chintan Pharma Chem results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 17 July 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Tatva Chintan Pharma Chem closed at ₹1,690.20 on 4 November 2026, up 12.7% from ₹1,500.20 a year earlier (7 November 2025) and down 40.6% over five years. Its highest weekly close since July 2021 was ₹2,843.30 on 4 November 2021.

Tatva Chintan Pharma Chem share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

282 weekly closes from 30 July 2021 to 4 November 2026.

4 Nov 2026: Tatva Chintan Pharma Chem closed at ₹1,690.20, up 2.8% on the week and down 3.0% on the month. Results for July to September 2026: Revenue up 75.0% and profit up 110.0% on a year earlier.

Earlier

• 11 Sep 2026: ex-date for a dividend of ₹2 a share.
• Our read, 19 Jul 2026: Tatva Chintan has transitioned from a pure Phase Transfer Catalyst (PTC) business to higher-margin pharma and agro intermediates, commissioning its Dahej block and initiating a greenfield Jolwa facility. Recent margin pressure stems from pricing lag and under-utilized capacity, but operating leverage will expand margins as peak pharma revenue commercializes.
• 17 Jul 2026: Tatva Chintan Pharma Chem held its results call for April to June 2026. Management guided: FY27 consolidated revenue growth 25-30% with operating margin goal 20-22%.

Our read of the business

Tatva Chintan has transitioned from a pure Phase Transfer Catalyst (PTC) business to higher-margin pharma and agro intermediates, commissioning its Dahej block and initiating a greenfield Jolwa facility. Recent margin pressure stems from pricing lag and under-utilized capacity, but operating leverage will expand margins as peak pharma revenue commercializes.

July to September 2026: Semiconductor qualification achieved; Pharma scaling.

Our read after the July to September 2026 results, written 19 July 2026.

Tatva Chintan Pharma Chem paid ₹2 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.12% at the ₹1,690.20 close on 4 November 2026. The last was a dividend of ₹2 a share, ex-date 11 September 2026.

Tatva Chintan Pharma Chem dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Tatva Chintan Pharma Chem Ltd paid out 11% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 9 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 17 July 2026, Tatva Chintan Pharma Chem's management guided: FY27 consolidated revenue growth 25-30% with operating margin goal 20-22%.

“I am extremely proud to share that our first batch produced on commercial plant scale was delivered to the customer during this quarter. This batch has been successfully qualified by the customer. We consider this to be one of Tatva Chintan's stellar achievements of the past decade. The significance of this achievement extends far beyond a single product. …”Chinthan Shah, on the call for April to June 2026

What management guided

• FY27 pharma molecules revenue ₹70-80 crores from three molecules (one commercial production Q1, two additional by Q3); full utilization potential ₹200 crore.
• FY27 Electrolyte Salts revenue ₹40-60 crores (goal 10% of total revenue mix); progression dependent on raw material supply chain normalization.
• New greenfield facility capital spending ₹200 crore approved by Board with groundbreaking July 20, 2026; 18-21 month operational timeline planned (management internally pushing 18-month acceleration); facility designed as fungible multi-product platform.
• New facility peak revenue capacity ₹300 crore at modeled asset turnover of 1.2-1.5x.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 17 July 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

What is changing at Tatva Chintan Pharma Chem, from the latest results and calls: pharma commercialization ramp and semiconductor validation.

• Pharma Commercialization Ramp. Three pharma molecules launching to deliver new revenue stream. ⚠ estimate
• Semiconductor Validation. Plant-scale qualification completed, opening pathway for future commercialization. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the July to September 2026 results, written 19 July 2026.

Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to operating margin remaining depressed.

Each change stops working if

• Pharma Commercialization Ramp: Customer validation for the remaining two molecules fails or is delayed.
• Semiconductor Validation: Competitor develops an alternative less-toxic chemistry before Tatva achieves full commercial scale.

The main risks

• Raw Material Inflation: Geopolitical disruption elevating amine prices. ✓ fact
• Working Capital Drag: Inventory days expanded, suppressing operating cash flow. ✓ fact

Our read after the July to September 2026 results, written 19 July 2026.

When Tatva Chintan Pharma Chem reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Electrolyte Salts quarterly progression toward ₹40-60 crore FY27 goal - track sequential ramp from Q1 base of ₹6 crore; validate raw material supply chain normalization post-Middle East crisis and confirm customer demand visibility translates to consistent quarterly ramping.

Tatva Chintan Pharma Chem is not on any of our India lists this week.

Tatva Chintan Pharma Chem Ltd earned ₹21.0 Cr of net profit in the Sep 2026 quarter, +110.0% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹42.0 Cr. Over 8 years profit has grown 17.0% a year on average. That is 9.7% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹10.0 Cr. 1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹42.0 Cr (+600.0% on the year before).

Why profit moved: revenue changed +75.0% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +379.5% and revenue +48.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY27-Q1. revenue ₹167 Cr and profit ₹16 Cr as reported.

FY27-Q2. revenue ₹217 Cr and profit ₹21 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Tatva Chintan Pharma Chem Ltd reported ₹217 Cr of revenue in the Sep 2026 quarter, +75.0% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 8 years it has grown 17.8% a year on average. The last full year, FY26, came in at ₹506 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Tatva is transitioning its pharma pipeline into commercial production, with one molecule launched in the first quarter and two more planned later in the year. This new revenue stream carries higher margins due to chemical complexity and will utilize the newly commissioned Dahej capacity.

The last four reported quarters add to ₹649 Cr.

FY26 revenue was ₹506 Cr, +32.1% on the year before.

Recent pace: the last four quarters grew +48.5% on average, against 17.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +49.2%, against +32.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +244.4%, against +91.0% a year (accelerating).

FY27-Q1. revenue ₹167 Cr and profit ₹16 Cr as reported.

FY27-Q2. revenue ₹217 Cr and profit ₹21 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Tatva Chintan Pharma Chem Ltd's operating margin was 19.0% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 9 years it has been between 9.0% and 25.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed −4.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY27-Q1. revenue ₹167 Cr and profit ₹16 Cr as reported.

FY27-Q2. revenue ₹217 Cr and profit ₹21 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Over the last 3 years, 197% of Tatva Chintan Pharma Chem Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹31.0 Cr of operating cash against ₹42.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹118 Cr of spending on assets, free cash was −₹87.0 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 197% of profit came in as cash: the cash cycle got 141 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 3.3× depreciation over three years. The next section checks what that spending is building.

Tatva Chintan Pharma Chem Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 310 days in FY26, up from 169 days in FY21. It spent ₹298 Cr on assets over the last 3 years. Customers take 86 days to pay, and stock sits for 319 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. The first commercial plant-scale batch for semiconductor applications was successfully qualified by the customer. While full commercialization requires additional trials, this validates the R&D capabilities and positions Tatva for a significant long-term growth vector.

At FY26 sales of ₹506 Cr, each day of that cycle ties up about ₹1.4 Cr, so roughly ₹430 Cr is tied up in the business at any time.

FY26: customers took 86 days to pay and stock sat for 319 days, about 10.5 months of sales sitting as stock, for a full cycle of 310 days, longer than FY21's 169.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 319 days. Customers pay about 86 days after that. Suppliers are paid at 95 days. Together that makes the 310-day cycle.

Spending on assets: ₹298 Cr over the last 3 years, against ₹91.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹25.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Tatva Chintan Pharma Chem Ltd's P/E is 61.9×, near the low end of its own history: it has been lower only 26% of the time. Its usual P/E (the middle reading) is 77.7×, over 5.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹26.90.

Why the multiple is where it is: over the past year earnings per share moved +636.9% while the price moved +12.7%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved −9.9% a year; about +3.0% a year came from earnings growth and about −12.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Tatva Chintan Pharma Chem Ltd's business is turning around. Profit growth has swung from −73.1% at its low to +244.4%, rising from a low 5 quarters ago, with ROCE steady at 3.5%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Tatva Chintan Pharma Chem Ltd's story is not scored yet against the checks our research set on 19 July 2026. Where it sits in its own cycle: Not stated in the research file. Still open: Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to OPM remaining depressed.

NOT YET CHECKED

Our read, 19 July 2026. Capex commissioning and Pharma/Agro scale-up masking underlying margin improvement via optical high working capital phase.

From the numbers. The business is in an early expansion phase with trailing earnings depressed by under-utilized capacity and launch-phase costs.

From the price. Price stage 2, week 27, above its 200-day line, relative strength falling.

From the research. Capex commissioning and Pharma/Agro scale-up masking underlying margin improvement via optical high working capital phase.

Where they disagree. The business is in an early expansion phase with trailing earnings depressed by under-utilized capacity and launch-phase costs.

What is proven. Capex commissioning and Pharma/Agro scale-up masking underlying margin improvement via optical high working capital phase.

What is not proven yet. Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to OPM remaining depressed.

What would change our mind. Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to OPM remaining depressed.

The test written in advance. Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to OPM remaining depressed. Measured by: the thesis as written as stated by the next result.

The test written in advance. Raw Material Inflation. Measured by: Raw Material Inflation Gross margin percentage dropping significantly in subsequent quarters. by the next result.

The test written in advance. Working Capital Drag. Measured by: Working Capital Drag Inventory days continuing to expand without proportional revenue growth. by the next result.

What the company does. Tatva Chintan has transitioned from a pure Phase Transfer Catalyst (PTC) business to higher-margin pharma and agro intermediates, commissioning its Dahej block and initiating a greenfield Jolwa facility. Recent margin pressure stems from pricing lag and under-utilized capacity, but operating leverage will expand margins as peak pharma revenue commercializes. The ROE optical depression reflects the launch phase channel stocking and early utilization, which will mean-revert as volume absorption occurs.

The key numbers to watch, and the level that would change the picture

Everything further down this page is evidence for or against these.

What the surface reading misses. The surface reading is: Margin is compressed relative to history. The research reads it further: Raw material inflation (amines up 30-40%) encountered a 40-50 day pass-through lag; margins will revert as pricing catches up and utilization increases.

What the surface reading misses. The surface reading is: ROE indicates a low-quality or structurally impaired business. The research reads it further: ROE denominator (equity/assets) is inflated by recent capex commissioning and launch-phase inventory build, while the numerator (earnings) lags. This is an early-expansion optical distortion.

Sources: our stock research file (19 July 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

What Tatva Chintan Pharma Chem Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Greenfield Capex spending Revision · 17 July 2026. In the Jan 2026 call, management stated the first phase of the Jolva greenfield project would involve a capex of INR250-275 crores, with final drawings and estimation underway.

Jolva Project Groundbreaking Timeline Shifts · 17 July 2026. Management stated in the May 2026 call that the groundbreaking for the Jolva project was expected within the quarter, with the timeline having been pushed back 4-6 weeks due to design optimization.

SDA Capacity Utilization and Revenue Potential Contradiction · 17 July 2026. In the Jan 2026 call, management indicated SDA capacity utilization was at approximately 55% and that a 25-30% growth rate was expected, implying no need for major capex to support expansion. However, in the Jul 2026 call, management stated that beyond INR800-850 crores in total company revenue, new infrastructure would be needed, directly linking this constraint to SDA growth from the new Jolva facility, which contradicts the earlier statement that existing capacity was sufficient.

SDA Segment Growth Revised Downward · 16 May 2026. Management lowered their growth guidance for the Structured Directing Agents (SDA) segment from the 25% to 30% range projected in the Jan 2026 call to a more conservative goal of at least 20% in the May 2026 call. This revision reflects growing caution due to geopolitical uncertainties that were previously viewed as manageable.

Every quote above is taken word for word from the company’s own earnings calls.

The current sweep found routine exchange filings but no company-specific enforcement or fraud action.

Checked 30 August 2026.

Tatva Chintan Pharma Chem Ltd earned a ROCE of 7% in FY26. That is up from a low of 1% in FY25. Its return on capital used (ROIC) is 4.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a 8.3% net margin and 0.50× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a 8.3% net margin × 0.50× asset turnover × 1.29× leverage (assets divided by equity) ≈ 5.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 7.1% − 12.0% = −4.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 7.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 5.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Tatva Chintan Pharma Chem Ltd has total debt of ₹170 Cr against shareholder equity of ₹815 Cr as of Sep 2026, so its debt is 0.21× its equity, which is very little. Year by year, that ratio went from 0.25 in FY22 to 0.15 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions cut their stake in Tatva Chintan Pharma Chem Ltd by 3.6 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 3.2% of the company. Foreign institutions moved +1.0 points over the same period, to 4.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: −3.6 points over 8 quarters, to 3.2%; Foreign institutions: +1.0 points over 8 quarters, to 4.4%; Promoters: +0.0 points over 8 quarters, to 72.0%.

Why the owners changed: domestic institutions drove it (−3.6 points), with the other side taken by foreign institutions (+1.0 points). They reduced their stake.

For Tatva Chintan Pharma Chem Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

59.9 out of 100, rank 6 of 30 in Speciality Chemicals, with 93% of the evidence available.

Tatva Chintan Pharma Chem Ltd scores 59.9 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 6. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 28.7 + 8.5 + 11.3 + 11.4 = 59.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Tatva Chintan Pharma Chem ranks 6 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 59.9 out of 100.